2 weeks Ago By ABMN Staff
Public Employees Retirement Association of Colorado trimmed its position in shares of PTC Therapeutics, Inc. ( NASDAQ:PTCT – Free Report ) by 5.1% during the second quarter, HoldingsChannel.
com reports. The firm owned 8,727 shares of the biopharmaceutical company’s stock after selling 473 shares during the period. Public Employees Retirement Association of Colorado’s holdings in PTC Therapeutics were worth $267,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. XTX Topco Ltd bought a new position in PTC Therapeutics in the 2nd quarter valued at approximately $947,000. Renaissance Technologies LLC raised its stake in shares of PTC Therapeutics by 7.
4% during the second quarter. Renaissance Technologies LLC now owns 818,100 shares of the biopharmaceutical company’s stock valued at $25,017,000 after acquiring an additional 56,700 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of PTC Therapeutics by 20.
9% during the second quarter. DekaBank Deutsche Girozentrale now owns 29,016 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 5,016 shares during the period. American Century Companies Inc.
grew its stake in shares of PTC Therapeutics by 108.7% in the second quarter. American Century Companies Inc.
now owns 37,394 shares of the biopharmaceutical company’s stock worth $1,144,000 after purchasing an additional 19,475 shares during the last quarter. Finally, VitalStone Financial LLC acquired a new stake in PTC Therapeutics in the second quarter valued at $286,000. Insider Buying and Selling at PTC Therapeutics In other news, CFO Pierre Gravier sold 2,269 shares of the company’s stock in a transaction on Tuesday, July 16th.
The shares were sold at an average price of $34.02, for a total value of $77,191.38.
Following the completion of the sale, the chief financial officer now owns 53,531 shares in the company, valued at approximately $1,821,124.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink .
Company insiders own 5.50% of the company’s stock. PTC Therapeutics Price Performance PTC Therapeutics ( NASDAQ:PTCT – Get Free Report ) last posted its earnings results on Thursday, August 8th.
The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.
16). The company had revenue of $186.70 million for the quarter, compared to the consensus estimate of $192.
12 million. On average, sell-side analysts expect that PTC Therapeutics, Inc. will post -5.
09 EPS for the current year. Wall Street Analyst Weigh In Several research analysts have commented on PTCT shares. UBS Group began coverage on PTC Therapeutics in a report on Monday, August 26th.
They set a “buy” rating and a $47.00 target price on the stock. JPMorgan Chase & Co.
reiterated an “overweight” rating and issued a $53.00 target price on shares of PTC Therapeutics in a report on Thursday, June 20th. Barclays raised their price target on shares of PTC Therapeutics from $25.
00 to $31.00 and gave the stock an “equal weight” rating in a report on Friday, August 9th. Bank of America upped their price objective on shares of PTC Therapeutics from $25.
00 to $32.00 and gave the company an “underperform” rating in a research note on Friday, June 21st. Finally, Morgan Stanley lifted their target price on shares of PTC Therapeutics from $30.
00 to $32.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock.
Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $37.64. Read Our Latest Research Report on PTC Therapeutics PTC Therapeutics Company Profile ( Free Report ) PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.
The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Featured Stories Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc.
( NASDAQ:PTCT – Free Report ). Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
